Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
Lett Appl Microbiol ; 77(5)2024 May 03.
Artigo em Inglês | MEDLINE | ID: mdl-38658187

RESUMO

Species from Candida parapsilosis complex are frequently found in neonatal candidemia. The antifungal agents to treat this infection are limited and the occurrence of low in vitro susceptibility to echinocandins such as micafungin has been observed. In this context, the chaperone Hsp90 could be a target to reduce resistance. Thus, the objective of this research was to identify isolates from the C. parapsilosis complex and verify the action of Hsp90 inhibitors associated with micafungin. The fungal identification was based on genetic sequencing and mass spectrometry. Minimal inhibitory concentrations were determined by broth microdilution method according to Clinical Laboratory and Standards Institute. The evaluation of the interaction between micafungin with Hsp90 inhibitors was realized using the checkerboard methodology. According to the polyphasic taxonomy, C. parapsilosis sensu stricto was the most frequently identified, followed by C. orthopsilosis and C. metapsilosis, and one isolate of Lodderomyces elongisporus was identified by genetic sequencing. The Hsp90 inhibitor geladanamycin associated with micafungin showed a synergic effect in 31.25% of the isolates, a better result was observed with radicicol, which shows synergic effect in 56.25% tested yeasts. The results obtained demonstrate that blocking Hsp90 could be effective to reduce antifungal resistance to echinocandins.


Assuntos
Antifúngicos , Candida parapsilosis , Candidemia , Proteínas de Choque Térmico HSP90 , Micafungina , Humanos , Recém-Nascido , Antifúngicos/farmacologia , Benzoquinonas/farmacologia , Candida parapsilosis/efeitos dos fármacos , Candida parapsilosis/isolamento & purificação , Candida parapsilosis/genética , Candidemia/microbiologia , Farmacorresistência Fúngica , Sinergismo Farmacológico , Equinocandinas/farmacologia , Proteínas de Choque Térmico HSP90/antagonistas & inibidores , Proteínas de Choque Térmico HSP90/metabolismo , Proteínas de Choque Térmico HSP90/genética , Lactamas Macrocíclicas/farmacologia , Lipopeptídeos/farmacologia , Micafungina/farmacologia , Testes de Sensibilidade Microbiana
2.
Braz J Microbiol ; 54(2): 817-825, 2023 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-36892755

RESUMO

Candidemia is responsible for substantial morbidity and mortality in neonatal intensive care units and represents a challenge due to the complexity of hospitalized neonates, the deficiency in approved and precise diagnostic techniques, and the increasing number of species resistant to antifungal agents. Thus, the objective of this study was to detect candidemia among neonates evaluating the risk factors, epidemiology, and antifungal susceptibility. Blood samples were obtained from neonates with suspected septicemia, and the mycological diagnosis was based on yeast growth in culture. The fungal taxonomy was based on classic identification, automated system, and proteomic, when necessary molecular tools were used. The in vitro susceptibility tests were performed according to the broth microdilution method from Clinical and Laboratory Standards Institute. Statistical analysis was performed using the R software version R-4.2.2. The prevalence of neonatal candidemia was 10.97%. The major risk factors involved were previous use of parenteral nutrition, exposure to broad-spectrum antibiotics, prematurity, and prior use central venous catheter, but only this last was statistically associated with mortality risk. Species from Candida parapsilosis complex and C. albicans were the most frequent. All isolates were susceptible to amphotericin B, except C. haemulonii that also exhibited elevated MICs to fluconazole. C. parapsilosis complex and C. glabrata exhibit the highest MICs to echinocandins. Considering these data, we emphasize that an effective management strategy to reduce the impact of neonatal candidemia should involve the knowledge of risk factors, rapid and precise mycological diagnostic, and tests of antifungal susceptibility to help in the selection of an appropriate treatment.


Assuntos
Candidemia , Recém-Nascido , Humanos , Candidemia/microbiologia , Antifúngicos/farmacologia , Antifúngicos/uso terapêutico , Candida , Brasil/epidemiologia , Unidades de Terapia Intensiva Neonatal , Proteômica , Fluconazol , Farmacorresistência Fúngica , Fatores de Risco , Candida glabrata , Candida albicans , Candida parapsilosis , Testes de Sensibilidade Microbiana
3.
Braz J Microbiol ; 39(1): 59-60, 2008 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-24031179

RESUMO

Fungal infections are increasingly being reported in immuno-compromised patients. In this study we report a case of systemic Trichosporon cutaneum infection in an infant with Wilms' tumor. This is the first time that an invasive infection for T. cutaneum has been reported in a Wilms' tumor patient.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA